HEPATITIS B and C THERAPY | VIRAL INFECTION | MULTIPLE SCLEROSIS
Assess effectivity of IFN-α therapy of HBV and HCV patients
Monitoring of neutralizing Abs in IFN-β therapy
Virus or bacterial infections
MxA is a marker of viral infection
IFN-α treatment of hepatitis B and C patients
MxA (myxovirus resistance protein 1), a protein with selective activity against certain viruses, is an accepted specific indicator of type I IFN activity.
MxA expression may be used to asses effectivity of IFN-α therapy of HBV and HCV patients. Hepatitis C virus (HCV) patients who express increased amounts of MxA mRNA in their PBMC during IFN-α treatment are most likely to obtain a long-term benefit. Another study showed that MxA mRNA induced by IFN-α might predict sustained virologic responses to IFN-α treatment in chronic HBV patients.
In newborns and infants
MxA differentiates patients with a viral infection from patients with bacterial infection and healthy controls.
Determination of MxA is used to avoid the inappropriate use of antibiotics, especially in newborns. Moreover, the immature immune system of newborns and infants poorly respond to infection.
In postoperative care - Distinguish virus infection
Many patients suffer febrile diseases soon after allogeneic stem cell transplantation. MxA is a useful marker to detect viral infections and distinguish them from acute graft-versus-host disease after allogeneic cell transplantation.
MxA Protein Human ELISAManufactured by BioVendor
|Cat. No.||Size|| Price
|RD194349200R||96 wells (1 kit)||595 €|
In multiple sclerosis patients, low MxA levels reflect reduced efficacy of IFN therapy
Multiple sclerosis (MS) is a multi-organ autoimmune disease affecting the central nervous system of young adults and is the most common autoimmune inflammatory demyelinating disease worldwide. It is a disabling neurological disease; local paralysis, incoordination of walking, double vision, and physical weakness are the prevalent symptoms of MS.
IFN-beta is an efficacious first-line drug for relapsing MS, by reducing the relapse rate, disability and magnetic resonance imaging (MRI) disease burden. Up to 30–40% of MS patients treated with IFN may develop neutralizing antibodies (NAbs) to IFN-β. NAbs are associated with reduced treatment efficacy, disease relapse, and progression.
MxA, the product of the MX1 gene plays an important role in the antiviral activity of the organism. It is expressed in response to IFN-β (or IFN-α) in the cytoplasm of sensitive cells. In MS patients, MxA correlates with therapeutic actions of IFN and is not influenced by disease activity. The absence of MxA reflects the complete loss of IFN bioactivity due to the presence of NAbs.
Do you want to see technical parameters of MxA Protein ELISA?
Is MxA Protein (myxovirus resistance protein 1) a potential biomarker for differentiating viral from bacterial infections?